Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (ticker: LACQ) is a clinical-stage pharmaceutical company specializing in abuse-deterrent formulations for opioid and stimulant therapies, operating within the life sciences and specialty pharmaceuticals sector. The company entered the public markets through a de-SPAC transaction completed in 2021 and has maintained its SEC reporting obligations since that listing. On January 8, 2026, Ensysce filed an 8-K current report with the SEC under accession number 0001493152-26-000994, flagging material developments for investors. The company remains an active post-merger public entity in the biotech and drug-development space. To access full filing histories, deal timelines, sponsor profiles, and real-time SPAC data on Ensysce Biosciences and hundreds of other transactions, sign up for SpacDesk at spacdesk.com.